Anti-Zaire Ebola Virus VP35 Protein, N-Terminal [10C7] Antibody
![Anti-Zaire Ebola Virus VP35 Protein [10C7] Antibody](https://www.kerafast.com/MediaStorage/Product/Images/Large/1009_2001202001263010080.jpg "Anti-Zaire Ebola Virus VP35 Protein, N-Terminal [10C7] Antibody")
This mouse IgG2b monoclonal antibody [10C7] was generated against DNA immunization followed by recombinant protein and is specific for the N-terminal portion of Zaire ebolavirus polymerase cofactor VP35.
Highlights
- Reacts with N-terminal portion of Zaire ebolavirus polymerase cofactor VP35
- Suitable for Western Blot applications
Ebola virus (EBOV), or sometimes referred to as Zaire ebolavirus is one of the five identified Ebola virus species. Zaire ebolavirus is a virological taxon that comes from the genus, Ebolvarius, family Filoviridae and the order Mononegavirales. Ebola, often fatal has been shown to cause hemorrhagic fever in humans and other mammals including monkeys and chimpanzees. Polymerase cofactor VP35 acts as a polymerase cofactor in the RNA polymerase transcription and replication complex. It prevents establishment of cellular antiviral state by blocking virus-induced phosphorylation and activation of interferon regulatory factor 3 (IRF3). This blockage is produced through the interaction with and inhibition of host IKBKE and TBK1. VP35 also inhibits the antiviral effect mediated by the host interferon-induced, double-stranded RNA-activated protein kinase EIF2AK2/PKR.
From the laboratory of Christopher F. Basler, PhD, Icahn School of Medicine at Mount Sinai
Part of The Investigator's Annexe program.
This mouse IgG2b monoclonal antibody [10C7] was generated against DNA immunization followed by recombinant protein and is specific for the N-terminal portion of Zaire ebolavirus polymerase cofactor VP35.
Highlights
- Reacts with N-terminal portion of Zaire ebolavirus polymerase cofactor VP35
- Suitable for Western Blot applications
Ebola virus (EBOV), or sometimes referred to as Zaire ebolavirus is one of the five identified Ebola virus species. Zaire ebolavirus is a virological taxon that comes from the genus, Ebolvarius, family Filoviridae and the order Mononegavirales. Ebola, often fatal has been shown to cause hemorrhagic fever in humans and other mammals including monkeys and chimpanzees. Polymerase cofactor VP35 acts as a polymerase cofactor in the RNA polymerase transcription and replication complex. It prevents establishment of cellular antiviral state by blocking virus-induced phosphorylation and activation of interferon regulatory factor 3 (IRF3). This blockage is produced through the interaction with and inhibition of host IKBKE and TBK1. VP35 also inhibits the antiviral effect mediated by the host interferon-induced, double-stranded RNA-activated protein kinase EIF2AK2/PKR.
From the laboratory of Christopher F. Basler, PhD, Icahn School of Medicine at Mount Sinai
Part of The Investigator's Annexe program.
| Product Type: | Antibody |
| Antigen: | Zaire ebolavirus polymerase cofacter VP35 |
| Accession ID: | Q05127, AF086833.2 |
| Molecular Weight: | 35 kDa |
| Isotype: | IgG2b |
| Clonality: | Monoclonal |
| Clone Name: | 10C7 |
| Reactivity: | Virus |
| Immunogen: | DNA immunization followed by recombinant protein |
| Species Immunized: | Mouse |
| Epitope: | Within the N-terminal portion of protein |
| Purification Method: | Protein G Affinity |
| Buffer: | 0.1M Sodium Phosphate, pH 7.4, 0.15M NaCl, 0.05% (w/v) Sodium Azide |
| Tested Applications: | WB (1:1000) |
| Storage: | -20C |
| Shipped: | Cold packs |
- Radwańska MJ, Jaskółowski M, Davydova E, Derewenda U, Miyake T, Engel DA, Kossiakoff AA, Derewenda ZS. The structure of the C-terminal domain of the nucleoprotein from the Bundibugyo strain of the Ebola virus in complex with a pan-specific synthetic Fab. Acta Crystallogr D Struct Biol. 2018 Jul 1;74(Pt 7):681-689. View Article
- Greenberg A, Huber BR, Liu DX, et al. Quantification of Viral and Host Biomarkers in the Liver of Rhesus Macaques: A Longitudinal Study of Zaire Ebolavirus Strain Kikwit (EBOV/Kik). Am J Pathol. 2020;190(7):1449-1460. View Article
If you publish research with this product, please let us know so we can cite your paper.
